Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Befovacimab, an antibody targeting TFPI.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zilovertamab, an antibody targeting ROR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vudalimab, an antibody targeting CTLA-4 × PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vixarelimab, an antibody targeting OSMR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Unasnemab, an antibody targeting RGMA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Uliledlimab, an antibody targeting CD73.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Torudokimab, an antibody targeting IL33.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Surzebiclimab, an antibody targeting HAVCR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sudubrilimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sotigalimab, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pimivalimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ordesekimab, an antibody targeting IL15.